A carregar...
The “rights” of precision drug development for Alzheimer’s disease
There is a high rate of failure in Alzheimer’s disease (AD) drug development with 99% of trials showing no drug-placebo difference. This low rate of success delays new treatments for patients and discourages investment in AD drug development. Studies across drug development programs in multiple diso...
Na minha lista:
| Publicado no: | Alzheimers Res Ther |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6717388/ https://ncbi.nlm.nih.gov/pubmed/31470905 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-019-0529-5 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|